ScholarLens Back to search
2009•Journal of Medical ForumRequires access

Clinical Research of Acute Myeloid Leukemia

Zhang Yusheng

Open publisher page 0 citations

Abstract

Objective To investigate the efficacy of FLAG regimen in refractory and relapse acute myeloid leukemia.Methods Fludarabine 50mg/d,1～5days,Ara-c 2g/d,1～5days and G-CSF 300μg/d were used to treat 20 cases of refractory and relapsed leukemia.Results Two treatment courses later,The rate of complete remission was 65%(13/20),the rate of partial remission 10%(2/20),and the overall response rate 75.0%.Main toxicities were myelosupression and neutropenia,gastrointestinal side effects.No treatment-related death was observed.Conclusion FLAG regimen consisting of Fludarabine,Intermediate-dose Ara-C,G-CSF is very effective for refractory or relapsed acute leukemia and is well tolerated.The treatment-related mortality rate is low.So it provides a treatment choice and a chance of allo-SCT for these patients.

About this research paper

What this paper is about

Objective To investigate the efficacy of FLAG regimen in refractory and relapse acute myeloid leukemia.Methods Fludarabine 50mg/d,1～5days,Ara-c 2g/d,1～5days and G-CSF 300μg/d were used to treat 20 cases of refractory and relapsed leukemia.Results Two treatment courses later,The rate of complete remission was 65%(13/20),the rate of partial remission 10%(2/20),and the overall response rate 75.0%.Main toxicities were myelosupression and neutropenia,gastrointestinal side effects.No treatment-related death was observed.Conclusion FLAG regimen consisting of Fludarabine,Intermediate-dose Ara-C,G-CSF is very effective for refractory or relapsed acute leukemia and is well tolerated.The treatment-related mortality rate is low.So it provides a treatment choice and a chance of allo-SCT for these patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the efficacy of FLAG regimen in refractory and relapse acute myeloid leukemia.Methods Fludarabine 50mg/d,1～5days,Ara-c 2g/d,1～5days and G-CSF 300μg/d were used to treat 20 cases of refractory and relapsed leukemia.Results Two treatment courses later,The rate of complete remission was 65%(13/20),the rate of partial remission 10%(2/20),and the overall response rate 75.0%.Main toxicities were myelosupression and neutropenia,gastrointestinal side effects.No treatment-related death was observed.Conclusion FLAG regimen consisting of Fludarabine,Intermediate-dose Ara-C,G-CSF is very effective for refractory or relapsed acute leukemia and is well tolerated.The treatment-related mortality rate is low.So it provides a treatment choice and a chance of allo-SCT for these patients.

Key concepts: Fludarabine, Myeloid leukemia, Medicine, Refractory (planetary science), Flag (linear algebra), Regimen, Neutropenia, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Research of Acute Myeloid Leukemia — Research Paper | ScholarLens